DNAPrint genomics Upgrades Genotyping Platform

DNAPrint genomics Upgrades Genotyping Platform 


SARASOTA, Fla., July 12  /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC:DNAG) (BULLETIN BOARD: DNAG)  today announced an upgrade in the throughput
and cost efficiency of its automated Beckman Coulter GenomeLab SNPstream
genotyping platform.

Beckman Coulter, which manufactures laboratory instrument systems for
diagnostic tests and biological research, upgraded DNAPrint's SNPstream Ultra
High Throughput (UHT) instrument from 12-plex to 48-plex capability, allowing
for an approximate four-fold increase in throughput, or the rate at which it
can read DNA sequences.  The instrument reads DNA sequence from microarray
slides (so-called DNA chips) containing about 18,000 nanospots.  Since the
upgrade in capability does not require commensurate increases in labor, the
Company expects to enjoy a significant reduction in price per genotype.  The
upgrade was part of a planned expansion of DNAPrint's laboratory size, presence
and capabilities as the Company grows to handle larger numbers of drug and
diagnostics development projects.

"The upgrade will generate cost savings for the Company, a portion of which
will be passed on to our clients," said Richard Gabriel, President and Chief
Executive Officer of DNAPrint genomics.  "We continue to improve our operations
to meet the growing demand we are experiencing, not just in our internal
research and development projects, but also in customer sales in Forensics,
Ancestry and Genotyping services as well."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of
genomics-based products and services focused on drug development,
pharmacogenomic diagnostic tests, forensics technology and consumer genetic
tests. The Company's first theranostic product (drug/test combination) is PT-
401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia
in renal dialysis patients (end stage renal disease). Currently in pre-
clinical development, PT-401 will be targeted to patients with a genetic
profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward-
looking statements. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected,
including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory approvals,
competition, intellectual property of others, and patent protection and
litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-
looking statements contained herein to reflect any change in DNAPrint's
expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based.

   Company Contact:
   Richard Gabriel
   CEO and President
   941 336-3400
        -or-
   Ron Stabiner
   The Wall Street Group, Inc.
   212-888-4848


DATASOURCE: DNAPrint genomics



CONTACT:  Richard Gabriel, CEO and President, DNAPrint genomics,

[phone]; or Ron Stabiner, The Wall Street Group, Inc.,

[phone], for DNAPrint genomics



Web site:  http://www.dnaprint.com/ 

Copyright